secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2026-08-04T20:05:36+00:00
Accession:  0000950103-26-011876
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen reports Q2 2026 net income of $20.1M; PAPZIMEOS revenue $53.1M, more than double prior quarter
--------------------------------------------------------------------------------

- PAPZIMEOS net revenue $53.1M in Q2 2026, more than double prior quarter; total revenues $55.0M.
- Net income $20.1M ($0.06 basic EPS) vs net loss $26.6M ($0.09 loss) in Q2 2025.
- Cash, equivalents, and investments $38.7M as of June 30, 2026; expects cash flow break-even by end of 2026.
- FDA granted PAPZIMEOS seven-year market exclusivity; patient hub enrollment over 500 patients.
- MAA for PAPZIMEOS under review by EMA; PRGN-2009 pipeline update expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/0000950103-26-011876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/dp251262_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-011876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer